PMID- 15489560
OWN - NLM
STAT- MEDLINE
DCOM- 20061227
LR  - 20130520
IS  - 1420-4096 (Print)
IS  - 1420-4096 (Linking)
VI  - 28
IP  - 1
DP  - 2005
TI  - Effects of treatment with epoetin beta on outcomes in patients with anaemia and 
      chronic heart failure.
PG  - 41-7
AB  - Anaemia is frequently found in patients with chronic heart failure (CHF) and has 
      been associated with an increase in mortality and morbidity, impaired cardiac and 
      renal function and a reduced quality of life (QoL) compared with non-anaemic CHF 
      patients. Correction of anaemia with recombinant human erythropoietin (epoetin) 
      has been associated with an improvement in CHF in both controlled and 
      uncontrolled studies. The present study describes our findings in a series of 78 
      consecutive patients with symptomatic CHF and anaemia (haemoglobin (Hb) level 
      <12.0 g/dl) treated with epoetin beta and, if necessary, intravenous iron 
      sucrose. Over a mean observation period of 20.7 +/- 12.1 months, mean Hb levels 
      increased from 10.2 +/- 1.1 to 13.5 +/- 1.2 g/dl, p < 0.01. New York Heart 
      Association (NYHA) functional class, left ventricular ejection fraction (LVEF) 
      were significantly improved and the number of hospitalizations was significantly 
      reduced with the period before treatment (all p < 0.01). Serum creatinine and 
      creatinine clearance (CCr) were 2.2 +/- 0.9 mg/dl and 32.5 +/- 26.5 ml/min, 
      respectively, at baseline, and remained stable over the observation period. 
      Interestingly, >90% of the patients had concomitant mild-to-moderate chronic 
      kidney disease at baseline and study end (CKD), as defined by the accepted 
      diagnostic criterion of a CCr <60 ml/min. CONCLUSIONS: The correction of the 
      anaemia with epoetin beta together with initial intravenous iron supplementation, 
      resulted in significant improvements in NYHA class and cardiac function, and a 
      reduction in hospitalization rate. Moreover, renal function was maintained stable 
      in most patients.
FAU - Silverberg, Donald S
AU  - Silverberg DS
AD  - Department of Nephrology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. 
      donald@netvision.net.il
FAU - Wexler, Dov
AU  - Wexler D
FAU - Blum, Miriam
AU  - Blum M
FAU - Iaina, Adrian
AU  - Iaina A
FAU - Sheps, David
AU  - Sheps D
FAU - Keren, Gad
AU  - Keren G
FAU - Scherhag, Armin
AU  - Scherhag A
FAU - Schwartz, Doron
AU  - Schwartz D
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20041015
PL  - Switzerland
TA  - Kidney Blood Press Res
JT  - Kidney & blood pressure research
JID - 9610505
RN  - 0 (Recombinant Proteins)
RN  - 0 (epoetin beta)
RN  - 11096-26-7 (Erythropoietin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia/blood/complications/*drug therapy/mortality
MH  - Case-Control Studies
MH  - Chronic Disease
MH  - Erythropoietin/*administration & dosage
MH  - Female
MH  - Heart Failure/blood/complications/*drug therapy/mortality
MH  - Hospitalization
MH  - Humans
MH  - Kidney Diseases/blood/complications/drug therapy/mortality
MH  - Male
MH  - Recombinant Proteins
EDAT- 2004/10/19 09:00
MHDA- 2006/12/28 09:00
CRDT- 2004/10/19 09:00
PHST- 2004/09/21 00:00 [accepted]
PHST- 2004/10/19 09:00 [pubmed]
PHST- 2006/12/28 09:00 [medline]
PHST- 2004/10/19 09:00 [entrez]
AID - 81621 [pii]
AID - 10.1159/000081621 [doi]
PST - ppublish
SO  - Kidney Blood Press Res. 2005;28(1):41-7. doi: 10.1159/000081621. Epub 2004 Oct 
      15.